MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT06277154 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
148
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

HRYZ Biotech Co.

Collaborators